MARÍA PILAR
ESCRIBANO SUBÍAS
Profesora asociada de Ciencias de la Salud
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (21)
2024
-
Assessing the clinical benefit, safety, and patient-reported outcomes with the use of the PAHcare™ digital platform in pulmonary arterial hypertension: a pilot study
Frontiers in Public Health, Vol. 12
-
Risk Stratification in Pulmonary Veno-Occlusive Disease
Archivos de Bronconeumologia
-
Simplified risk stratification based on cardiopulmonary exercise test: A Spanish two-center experience
Pulmonary Circulation, Vol. 14, Núm. 1
2023
-
Usefulness of genetics for clinical reclassification and refinement of prognostic stratification in pulmonary arterial hypertension
Revista Espanola de Cardiologia, Vol. 76, Núm. 6, pp. 460-467
2022
-
Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)
Scientific Reports
-
Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry
Clinical Microbiology and Infection, Vol. 28, Núm. 2, pp. 260-266
-
Evaluation of a digital health system (PAHcare™) for routine care of patients with pulmonary arterial hypertension: The CBS-PAH study protocol
Frontiers in Public Health, Vol. 10
-
Global Emergence of Resistance to Fluconazole and Voriconazole in Candida parapsilosis in Tertiary Hospitals in Spain During the COVID-19 Pandemic
Open Forum Infectious Diseases, Vol. 9, Núm. 11
-
Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension
Scientific reports, Vol. 12, Núm. 1, pp. 5289
-
Phenotypes of idiopathic pulmonary arterial hypertension
The Lancet Respiratory Medicine
2021
-
Azole and amphotericin B MIC values against aspergillus fumigatus: High agreement between spectrophotometric and visual readings using the EUCAST EDef 9.3.2 procedure
Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 1
-
Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain
Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1170.e1-1170.e7
-
Chronic thromboembolic pulmonary hypertension in Spain: a decade of change
Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 384-392
-
From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?
Advances in Therapy, Vol. 38, Núm. 4, pp. 1860-1875
-
Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
Respiratory Medicine, Vol. 178
2020
-
Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4
PLoS ONE, Vol. 15, Núm. 4
2019
-
Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry
International Journal of Cardiology, Vol. 275, pp. 158-164
2018
-
Variable Expressivity of a Founder Mutation in the EIF2AK4 Gene in Hereditary Pulmonary Veno-occlusive Disease and Its Impact on Survival
Revista Espanola de Cardiologia, Vol. 71, Núm. 2, pp. 117-118
2014
-
Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?
International Journal of Cardiology, Vol. 171, Núm. 1, pp. 15-23
2013
-
Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation
Clinical Transplantation, Vol. 27, Núm. 6